Progressive Supranuclear Palsy (PSP) represents the prototypical 4-repeat (4R) tauopathy, characterized by the preferential accumulation of hyperphosphorylated 4R tau isoforms in neurons and glia. Unlike Alzheimer's disease, which features an equal mixture of 3R and 4R tau isoforms, PSP demonstrates a selective predominance of 4R tau, reflecting distinct molecular pathophysiology[@dickinson2023]. This page synthesizes the molecular mechanisms underlying PSP tauopathy, including the basis for 4R tau aggregation, regional vulnerability patterns, glial pathology, and the relationship to related disorders including corticobasal degeneration (CBD) and corticobasal syndrome (CBS).
The pathogenesis of PSP involves a complex interplay of genetic predisposition (particularly the MAPT H1 haplotype), tau isoform dysregulation, post-translational modification abnormalities, and selective neuronal vulnerability. Understanding these mechanisms is essential for developing disease-modifying therapies targeting the core pathological process.
Progressive Supranuclear Palsy (PSP) represents the prototypical 4-repeat (4R) tauopathy, characterized by the preferential accumulation of hyperphosphorylated 4R tau isoforms in neurons and glia. Unlike Alzheimer's disease, which features an equal mixture of 3R and 4R tau isoforms, PSP demonstrates a selective predominance of 4R tau, reflecting distinct molecular pathophysiology[@dickinson2023]. This page synthesizes the molecular mechanisms underlying PSP tauopathy, including the basis for 4R tau aggregation, regional vulnerability patterns, glial pathology, and the relationship to related disorders including corticobasal degeneration (CBD) and corticobasal syndrome (CBS).
The pathogenesis of PSP involves a complex interplay of genetic predisposition (particularly the MAPT H1 haplotype), tau isoform dysregulation, post-translational modification abnormalities, and selective neuronal vulnerability. Understanding these mechanisms is essential for developing disease-modifying therapies targeting the core pathological process.
The microtubule-associated protein tau (MAPT) gene encodes six tau isoforms in the adult human brain through alternative splicing of exons 2, 3, and 10. Exclusion of exon 10 produces three-repeat (3R) isoforms, while inclusion produces four-repeat (4R) isoforms containing the third microtubule-binding repeat. In the normal adult brain, a 1:1 ratio of 3R:4R tau is tightly regulated to maintain physiological microtubule function[@dickinson2023].
In PSP, this balance is disrupted toward selective accumulation of 4R tau isoforms. This dysregulation occurs through multiple mechanisms:
Hyperphosphorylation of tau represents a central event in PSP pathogenesis. Phosphorylation at multiple sites reduces tau's microtubule-binding affinity, promotes its dissociation from microtubules, and facilitates aggregation into insoluble filaments.
While tau phosphorylation occurs across multiple sites in various tauopathies, PSP demonstrates distinct phosphorylation patterns:
| Phosphorylation Site | PSP Expression | CBD Expression | AD Expression |
|---------------------|----------------|----------------|---------------|
| Ser356 (pS356) | +++ | + | - |
| Ser262 (pS262) | ++ | ++ | + |
| Ser396 (pS396) | ++ | + | +++ |
| Ser404 (pS404) | ++ | ++ | +++ |
| Thr181 (pT181) | + | + | +++ |
The phosphorylation at Serine 356 represents the most PSP-specific marker, present in the majority of PSP cases but largely absent from other tauopathies[@dickinson2023]. This site is located in the second microtubule-binding repeat and shows strong correlation with markers of inflammation and apoptosis.
The aggregation of tau into filamentous structures follows a nucleation-dependent process:
The resulting filaments demonstrate distinct morphology from the paired helical filaments seen in Alzheimer's disease—straight, non-twisted filaments with C-shaped protofilament cores.
The subthalamic nucleus (STN) is a small, lens-shaped structure located in the basal ganglia, dorsal to the substantia nigra. It plays a critical role in motor control by providing excitatory (glutamatergic) input to the internal segment of the globus pallidus (GPi), thereby modulating the indirect motor pathway[@falzone2022].
In PSP, the subthalamic nucleus demonstrates early and severe involvement, contributing to the characteristic motor phenotype:
Several factors may contribute to the selective vulnerability of the subthalamic nucleus in PSP:
The early involvement of the subthalamic nucleus contributes to several core PSP features:
Tufted astrocytes represent a defining glial pathological feature of PSP, distinct from the astrocytic plaques seen in corticobasal degeneration. These tau-positive glial inclusions are characterized by:
The formation of tufted astrocytes involves several overlapping mechanisms:
Tufted astrocytes contribute to PSP pathogenesis through multiple mechanisms:
PSP and CBD share the 4R tauopathy classification but demonstrate important distinctions[@levin2022]:
| Feature | PSP | CBD |
|---------|-----|-----|
| Primary tau isoform | 4R | 4R |
| Filament morphology | Straight filaments | Mixed straight/twisted |
| Astrocytic pathology | Tufted astrocytes | Astrocytic plaques |
| Neuronal loss pattern | Brainstem predominant | Cortical predominant |
| Key clinical difference | Vertical gaze palsy | Apraxia |
Despite both being classified as 4R tauopathies, emerging evidence indicates distinct molecular mechanisms:
Corticobasal Syndrome (CBS) represents a clinical syndrome that can arise from multiple underlying pathologies, including PSP and CBD. This clinicopathological dissociation has important implications:
Despite differences, PSP, CBD, and related 4R tauopathies share common pathogenic mechanisms:
Tau pathology propagates through neural networks in a prion-like manner:
The progression of tau pathology in PSP follows a characteristic anatomical pattern:
This spreading pattern correlates with clinical progression, from early brainstem and basal ganglia features to later cortical involvement.
Understanding the molecular mechanisms of PSP tauopathy has identified several therapeutic targets:
| Target | Strategy | Status |
|--------|----------|--------|
| Tau aggregation | Small molecule inhibitors | Phase 1-2 |
| Tau clearance | Immunotherapies | Phase 2-3 |
| Tau phosphorylation | Kinase inhibitors | Research |
| 4R tau production | ASO-mediated splicing | Preclinical |
| Neuroinflammation | Anti-inflammatory agents | Research |
Molecular mechanisms inform biomarker development:
The recognition of distinct mechanisms in PSP vs. CBD has implications for precision medicine: